Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
- Data Reinforce the Clinically Meaningful Impact of INGREZZA in Adults with Huntington's Disease Chorea
- Findings Presented at the 2025 American Association of Neuroscience Nurses Neuroscience Advanced Practice Provider Symposium
SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT®-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA® (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
"This analysis reinforces the primary study findings, showing the consistent benefit of INGREZZA in reducing the involuntary movements of chorea that can affect any part of the body," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "Notably, the most significant improvements were seen in the arms and legs, which were the most severely affected at baseline. These results are meaningful because they show how INGREZZA alleviates chorea symptoms and therefore helps people with Huntington's disease in their everyday lives."
In the 12-week, Phase 3 KINECT-HD clinical trial, once-daily INGREZZA demonstrated a significant reduction in chorea severity, as measured by the Unified Huntington's Disease Rating Scale (UHDRS®) Total Maximal Chorea (TMC) score, which measures chorea in seven body regions (face, buccal-oral-lingual region, trunk, right and left upper extremities, right and left lower extremities). This post-hoc analysis was conducted to assess the effect of INGREZZA on chorea by individual body region.
In the KINECT-HD study, patients were randomized 1:1 to receive INGREZZA (n=64) at doses of 40 mg, 60 mg or 80 mg, or placebo (n=61). TMC scores at baseline were similar between treatment groups. Key findings from the post-hoc analysis include:
- More participants had potentially meaningful chorea improvements (a TMC score shift from ≥2 at screening/baseline to ≤1 at maintenance) with INGREZZA versus placebo for all affected body regions.
- Statistically significant chorea improvements were observed for the upper and lower extremities (P
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.